Table II.
Treatment results of two-stage revision of Methicillin-resistant group versus control group
| Treatment Results | Methicillin-resistant group (n:28) | Control group (n:29) | p-value |
|---|---|---|---|
| Interval period between stage (days) | 151.4 (range, 33-616) | 144.2 (range, 28-584) | 0.84 |
| Time to normal CRP (days) | 112.8 (range, 11-601) | 105 (range, 12-575) | 0.83 |
| Received reimplantation | 26 (92.8% | 26 (89.6%) | 0.66 |
| Single time cement spacer | 23 | 24 | |
| ≥times cement spacer | 2 | 1 | |
| Spacer and Girdlestone | 1 | 1 | |
| Never reimplantation | 2 (7.2%) | 3 (10.4%) | |
| Spacer retention | 1 | 3 | |
| Convert to Girdlestone | 1 | 0 | |
| Recurrency of infection | |||
| (after reimplantation) | 6 (23.1%) | 2 (7.6%) | 0.12 |
| I& | 0 | 0 | |
| One-stage revision | 1 | 0 | |
| Two-stage revision | 4 | 2 | |
| Girdlestone | 1 | 0 | |
| Overall infection control rate | 20/28 (71.4%) | 26/29 (89.6%) | 0.08 |
| HHS at final follow-up | 82.2 (range, 47-94) | 83.6 (range, 67-95) | 0.58 |
| ETO during 1st stage | 0.90 | ||
| Yes | 15 | 16 | |
| No | 13 | 13 | |
| Adverse events during spacer period | >0.05 | ||
| Spacer dislocation | 2 | 4 | |
| Periprosthetic fracture | 5 | 6 | |
| Cement dislodgement | 2 | 4 | |
| Adverse events after reimplantation | >0.05 | ||
| Aseptic loosening | 1 | 0 | |
| Dislocation | 2 | 2 | |
| Periprosthetic fracture | 0 | 1 |
CRP: C-reactive protein, I&D: irrigation and debridement; HHS: Harris hip score; ETO: extended trochanteric osteotomy.